A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE)

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs MSDC 0602 (Primary)
  • Indications Non-alcoholic fatty liver disease
  • Focus Therapeutic Use
  • Acronyms EMMINENCE
  • Sponsors Cirius Therapeutics
  • Most Recent Events

    • 11 Apr 2017 According to a Cirius Therapeutics media release, this trial was initiated by Octeta Therapeutics , but later on this company's name changed to Cirius Therapeutics.
    • 11 Apr 2017 According to a Cirius Therapeutics media release, company announced the completion of a Series A financing of up to $40 million led by Frazier Healthcare Partners and Novo A/S
    • 10 Apr 2017 Planned End Date changed from 1 Jul 2018 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top